Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C23H25F3N2OS.2ClH |
| Molecular Weight | 507.439 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.OCCN1CCN(CC\C=C2\C3=C(SC4=C2C=C(C=C4)C(F)(F)F)C=CC=C3)CC1
InChI
InChIKey=IOVDQEIIMOZNNA-MHKBYHAFSA-N
InChI=1S/C23H25F3N2OS.2ClH/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29;;/h1-2,4-8,16,29H,3,9-15H2;2*1H/b18-5-;;
DescriptionCurator's Comment: Description was created based on several sources, including https://www.medicines.org.uk/emc/PIL.5400.latest.pdf | http://www.lundbeck.com/upload/au/files/pdf/Fluanxol_CMI.pdf
Curator's Comment: Description was created based on several sources, including https://www.medicines.org.uk/emc/PIL.5400.latest.pdf | http://www.lundbeck.com/upload/au/files/pdf/Fluanxol_CMI.pdf
Flupenthixol is a thioxanthene antipsychotic used in the treatment of schizophrenia and other psychoses, with the exception of mania and psychomotor hyperactivity due to an activating effect associated with this drug. It may also be employed as an antidepressant. Flupenthixol has a wide range of pharmacological actions. Flupenthixol blocks dopaminergic receptors, thus interfering with dopaminergic transmission in the brain. Flupenthixol also inhibits serotonin 5-HT, histamine H1,
muscarinic and alpha-1 adrenergic receptors.
CNS Activity
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL217 Sources: DOI: 10.1016/B978-008055232-3.61770-2 |
|||
Target ID: CHEMBL2095200 |
|||
Target ID: CHEMBL2094251 |
|||
Target ID: CHEMBL231 |
|||
Target ID: CHEMBL2094109 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | FLUANXOL Approved UseFlupentixol Decanoate Injection and Flupentixol Dihydrochloride Tablets
Indication: Schizophrenia and allied psychoses, especially with symptoms such as hallucinations, delusions and thought disturbances along with apathy, lowered mood and withdrawal. |
|||
| Primary | FLUANXOL Approved UseFluanxol is used to treat depression in patients who may, or may not, also be showing signs of anxiety. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Allergotoxic brain reaction to flupentixol-depot]. | 1976 Mar-Apr |
|
| A controlled comparison of flupenthixol and amitriptyline in depressed outpatients. | 1976 May 8 |
|
| Effects of chronic treatment with antidepressants on aggressiveness induced by clonidine in mice. | 1982 |
|
| Neuroleptic malignant syndrome. | 1984 Jun 23 |
|
| Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. | 1994 Feb 1 |
|
| Expression and pharmacological characterization of the human D3 dopamine receptor. | 1994 Jan |
|
| Effect of flupenthixol on subjective and cardiovascular responses to intravenous cocaine in humans. | 2001 Nov 1 |
|
| [Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations]. | 2006 Jun |
|
| The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates. | 2012 Mar |
|
| Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes. | 2013 Jun |
Patents
Sample Use Guides
Fluanxol® (flupentixol) 0.5 mg and 1 mg film-coated tablets.
The starting dose is usually 1 mg daily taken as a single dose in the morning. This may be increased to 2 mg per day after one week. The maximum daily dose is 3 mg per day.
Fluanxol® (flupenthixol decanoate) Depot 20 mg/mL, Concentrated Depot 100 mg/mL.
Generally, the starting dose is 20 to 40 mg (1 to 2 mL). A second dose of 20 to 40 mg (1 to 2 mL) is usually given 4-10 days after the first injection, and further doses are given every 2 to 4 weeks for the majority of patients.
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
51529-01-2
Created by
admin on Fri Dec 15 17:52:10 GMT 2023 , Edited by admin on Fri Dec 15 17:52:10 GMT 2023
|
PRIMARY | |||
|
5282483
Created by
admin on Fri Dec 15 17:52:10 GMT 2023 , Edited by admin on Fri Dec 15 17:52:10 GMT 2023
|
PRIMARY | |||
|
96L0Z069N1
Created by
admin on Fri Dec 15 17:52:10 GMT 2023 , Edited by admin on Fri Dec 15 17:52:10 GMT 2023
|
PRIMARY | |||
|
DTXSID501017247
Created by
admin on Fri Dec 15 17:52:10 GMT 2023 , Edited by admin on Fri Dec 15 17:52:10 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
